Clinical Trials Sponsored by Tera Group

Total 8232 results

Tera Group

Recruiting

Validation of TERA Bio Station T101 of COVID-19 Tested Population.

COVID-19

Turkey
Tera Group

Not yet recruiting

Breath Samples Collection Clinical Trial, for Development of the TERA BioStation T101, Intended for CoV-19 Exhalation Products Detection.

COVID-19
Tera Group

Recruiting

Clinical Validation of Breath Analyser Tests for Diagnosis of COVID-19.

COVID-19

United Kingdom
Koffler Vision Group
Fera Pharmaceuticals, LLC

Terminated

Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Kennedy Medical Group
Teva Pharmaceuticals USA

Terminated

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

Chronic Migraine

United States
West German Study Group
Teva Pharmaceuticals USA

Active, not recruiting

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

Early Primary Breast Cancer

Germany
Groupe Francophone des Myelodysplasies
Teva Pharmaceuticals USA

Unknown

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

France
Borstkanker Onderzoek Groep
Roche Pharma AG; Teva Pharma

Completed

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer (Stop&Go)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Netherlands
German Breast Group
GlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USA

Completed

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
Teva Pharmaceuticals USA
Teva Pharmaceuticals, Inc.

Completed

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

Acne Vulgaris

United States
German Breast Group
Roche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor Pharma

Completed

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
Teva GTC

Terminated

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Crohn's Disease

Israel
Teva GTC

Completed

Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)

Traumatic Brain Injury

Israel
Teva Pharma

Completed

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

Metastatic Breast Cancer

Belgium
Teva GTC

Withdrawn

Open Label Extension Study to Protocol C2/13/DR-6MP-02 (OLE)

Crohn's Disease
Teva GTC

Terminated

One Year Extension Study To Protocol C2/5/TZ:MS-05

Multiple Sclerosis | Spasticity

Israel
Teva GTC

Completed

Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity

Muscle Spasticity

Israel
Teva GTC

Completed

Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients

Crohns Disease

Israel
Teva GTC

Completed

Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease

Crohn's Disease

Israel
Teva Pharmaceuticals USA
Teva Pharmaceuticals Development, Inc.

Completed

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Chronic Urticaria

United States
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer (ONCOTYPEDX)

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study (PETREC)

Lymphoma | Breast Cancer | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Non-small Cell Lung Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial) (PET LACE)

Adenocarcinoma | Cervical Cancer | Squamous Cell Carcinoma | Adenosquamous Carcinoma

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases (PETCAM)

Colorectal Cancer | Liver Metastases

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers (ELPET)

Non-small-cell Lung Carcinoma

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial)

Cancer of the Head and Neck

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)

Non-Small-Cell Lung Carcinoma

Canada
Bio-Thera Solutions

Not yet recruiting

A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Tyra Biosciences, Inc

Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)

Solid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma

United States
Bio-Thera Solutions

Not yet recruiting

BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer

Cervical Cancer

China
Bio-Thera Solutions

Recruiting

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Optic Neuromyelitis Spectrum Disease

China
Bio-Thera Solutions

Recruiting

Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients

Advanced or Metastatic Solid Tumors

China
Bio-Thera Solutions

Recruiting

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Neovascular (Wet) Age-related Macular Degeneration

China
Bio-Thera Solutions

Recruiting

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Advanced Solid Tumors

China
Tetra Discovery Partners

Recruiting

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

Fragile X Syndrome

United States
Bio-Thera Solutions

Recruiting

Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)

Uveitis

China
Bio-Thera Solutions

Recruiting

Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors

Advanced Solid Tumor

China
Bio-Thera Solutions

Recruiting

Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Vera Therapeutics, Inc.

Recruiting

Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

IgA Nephropathy | Berger Disease

United States
Bio-Thera Solutions

Completed

Clinical Study of the Safety and Efficacy of BAT5906 Injection

Diabetic Macular Edema

China
Teva Pharmaceuticals USA

Completed

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

Dyspareunia

United States, El Salvador, Honduras
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects

Psoriatic Arthritis

China
Bio-Thera Solutions

Active, not recruiting

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China

Advanced Solid Tumors

China
Bio-Thera Solutions

Active, not recruiting

A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects

Healthy Men

China
Bio-Thera Solutions

Completed

Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

Psoriatic Arthritis

China
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects

Psoriasis

China
Bio-Thera Solutions

Completed

Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects

Severe Asthma

China
Tela Bio Inc

Completed

Ventral Hernia Study Using OviTex Reinforced Bioscaffold

Hernia, Ventral

United States
Bio-Thera Solutions

Terminated

Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer

Advanced Solid Cancer

China

3

Subscribe